Emerging infectious diseases are defined as diseases in which incidence in humans has increased in the past two decades, or threatens to increase in the near future. They can be either newly discovered diseases or re-emerging diseases but are fundamentally capable of spreading very quickly beyond national boundaries, as well as becoming major public and global concerns for potentially resulting in a worldwide pandemic. It has been found that there has been an increase in the emergence of new infectious diseases, as around 30 new diseases have been identified in recent decades. It is believed that the fight against these infectious diseases is the development of vaccines against new viruses. Fortunately, with the gradual advancement of medical technology, researchers worldwide are developing new techniques of vaccine production to enhance its efficiency. Guests of this episode are Prof. Dr. Thiravat Hemachudha, head of the Thai Red Cross Emerging Infectious Diseases – Health Science Center, Chulalongkorn Hospital, and Asst. Prof. Dr. Suthira Taychakhoonavudh of the Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University. Dr. Suthira is also the chief executive and co-founder of Baiya Phytopharm, which is developing new kinds of vaccines.

Source
https://soundcloud.com/curadio1015/ep30-emerging-infectious-diseases-search-for-new-vaccines

About Baiya Phytopharm
Baiya Phytopharm is a clinical-stage biopharmaceutical company, focused on strengthening health security for all people using the BaiyaPharming platform protein for therapeutics and vaccines. Baiya Phytopharm’s plant-based technology is a cutting-edge solution that is quick, simple, and scalable, aiming to replace biotech fermenters with plants. Our team combines deep technology expertise in plant biotech, pharmaceutical production professions and clinical development capabilities to create biologics candidates with high unmet medical needs of the ASIA-Pacific region. We have generated a broad proprietary portfolio of candidates including monoclonal antibodies for cancer or infectious disease and new vaccines for neglected tropical diseases.